Hidden Risks Behind a "Healthy" Heart: What Stress Echocardiography Really Reveals
It’s easy to assume that if you have hypertrophic cardiomyopathy (HCM) yet feel fine, you’re in the clear. But here’s the twist—new long-term research shows that even symptom-free hearts may be hiding early warning signs of serious problems. And this is where stress echocardiography takes center stage.
A 13-year observational study has shed fresh light on how treadmill stress echocardiography (TSE) can expose physiological weaknesses that are otherwise invisible in asymptomatic adults with HCM. By analyzing patients who appeared healthy, researchers found that TSE not only assessed how well their hearts handled physical exertion but also predicted who faced greater long-term risks. These findings could play a major role in deciding when to intervene with treatments like septal reduction surgery—perhaps earlier than previously thought.
The Study That Changed Perspectives
Between 2002 and 2018, scientists examined 1,126 adults classified as New York Heart Association (NYHA) class I—meaning they were officially symptom-free—at a top-tier cardiology center. Every participant underwent both resting and exercise-based stress echocardiography, which measured metabolic equivalents (METs), percentage of age- and sex-predicted METs (%AGP-METs), and peak left ventricular outflow tract (LVOT) gradients. The researchers tracked serious outcomes including death, cardiac transplantation, and internal cardioverter-defibrillator (ICD) shocks.
Presented at the 2025 American Heart Association (AHA) Scientific Sessions and published in the Journal of the American College of Cardiology, the study delivered one unavoidable truth: not all "healthy" HCM patients are truly low-risk.
Many Symptom-Free Patients Still Struggle With Exercise
Here’s the part most people don’t expect—despite being officially labeled as asymptomatic, 37% of participants failed to achieve 85% of their predicted exercise capacity. In simpler terms, their hearts couldn’t perform at the level expected for their age and gender. This hidden shortfall points to real-world limitations that standard evaluations might miss.
Patients with obstructive HCM (oHCM), marked by an LVOT gradient of at least 30 mm Hg, showed even more concerning findings. They tended to have thicker heart walls, more mitral valve leakage, and lower MET results compared with those with nonobstructive HCM (nHCM). These subtle physiological differences often go unnoticed in routine exams but can carry long-term consequences.
Over a nearly 13-year follow-up, 18% of patients experienced major cardiac events: 173 deaths, 23 ICD interventions, and 7 heart transplants. Roughly 190 individuals eventually underwent myectomy, a surgical procedure to reduce muscle thickening. Interestingly, patients who reached at least 85% of predicted MET levels had a noticeably lower event rate (16%) than those who didn’t (20%). Could exercise performance be a key predictor of survival in a condition once thought defined mainly by anatomy?
Intervention Timing Matters More Than Ever
The researchers also compared patients based on whether they underwent septal reduction surgery. Those with either nHCM or oHCM who received myectomy enjoyed better long-term outcomes, with only 14% experiencing major events—versus 23% among obstructive patients who didn’t have surgery. That’s a striking difference, suggesting proactive treatment may be lifesaving even when symptoms seem absent.
In their conclusion, the investigators stressed that “asymptomatic” HCM patients must be evaluated carefully to confirm they are truly without physiological compromise. Identifying hidden obstruction early may help clinicians choose the best moment to intervene—before complications take hold. Still, they cautioned that more prospective trials are needed to confirm these observations.
Assessing the "Invisible"
So what’s the real takeaway? Stress echocardiography gives cardiologists an invaluable window into how the heart behaves under pressure. Traditional resting tests can miss dynamic changes that reveal genuine risk. As the authors behind this study noted, untreated obstruction or ongoing thickening of the heart muscle can remain silent for years—until it’s too late.
By uncovering these changes, TSE helps define who is truly asymptomatic and who may simply appear so. That information can guide crucial decisions regarding surgery, treatment intensity, and long-term monitoring.
Admittedly, the study has its limits. Being retrospective and single-centered means results might vary elsewhere. But its massive cohort size and extended follow-up strengthen the argument that exercise testing must not be overlooked in HCM management.
Something to Think About
If a condition can hide for years inside people who feel perfectly well, should cardiac screening rely more on functional testing like stress echocardiography rather than waiting for symptoms? And at what point should “preventative” interventions become the norm rather than the exception?
What do you think—is it time to redefine what it means to be truly asymptomatic in heart disease?
